Key result
TyG-ABSI identifies CKD risk, while ABSI predicts ~140% greater CVD mortality in established CKD.
Why the study?
The stage-specific utility of novel obesity indices, ABSI and TyG-ABSI, for CKD risk identification and mortality prediction within the same cohort was unclear.
Do novel obesity indices (ABSI and TyG-ABSI) predict CKD risk and mortality across the chronic kidney disease continuum?
Do novel obesity indices (ABSI and TyG-ABSI) predict CKD risk and mortality across the chronic kidney disease continuum?
TyG-ABSI is optimal for identifying CKD risk, whereas ABSI is superior for predicting mortality in established CKD, supporting stage-specific risk stratification.
Supports stage-specific obesity index use in CKD; extends risk models but hypothesis-generating pending validation.
This large-scale study utilizing the US National Health and Nutrition Examination Survey (NHANES, 1999-2018; n = 14,175) compared the diagnostic and prognostic utility of two novel obesity indices-A Body Shape Index (ABSI), and Triglyceride Glucose-A Body Shape Index (TyG-ABSI), evaluating their stage-specific utility for CKD risk identification and mortality prediction within the same cohort. TyG-ABSI demonstrated superior performance for identifying prevalent CKD, with the highest quartile (Q4) showing a significantly increased risk after full adjustment (OR = 1.58, 95% CI:1.23-2.03). Conversely, ABSI emerged as a stronger, nonlinear predictor of mortality in established CKD patients. Restricted cubic splines identified significant ABSI z-score thresholds: all-cause mortality risk increased steeply above z = 0.624 (HR = 1.44, 95% CI:1.17-1.77), and cardiovascular disease (CVD) mortality above z = 0.416 (HR = 1.35, 95% CI:1.09-1.83). After full adjustment, ABSI Q4 remained significantly associated with both all-cause (HR = 1.50) and CVD mortality (HR = 2.40), while TyG-ABSI associations attenuated. ABSI demonstrated superior discriminative accuracy for both all-cause mortality (area under the curve [AUC] = 0.68 vs. TyG-ABSI AUC = 0.66) and CVD mortality (AUC = 0.64 vs. TyG-ABSI AUC = 0.59). Subgroup analyses confirmed the robustness of ABSI for mortality prediction. These findings suggest a shift in the primary driver of adverse outcomes as CKD progresses: TyG-ABSI, capturing metabolic dysregulation, is optimal for identifying CKD risk, whereas ABSI, reflecting anatomical fat distribution, becomes the superior predictor of mortality in established CKD. This differential utility supports stage-specific risk stratification strategies and highlights the broader clinical relevance of obesity phenotyping for cardiovascular risk assessment, metabolic disease screening, and geriatric prognosis.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question. TyG-ABSI optimally identifies chronic kidney disease risk (OR 1.58), whereas ABSI is a superior predictor of cardiovascular (HR 2.40) and all-cause mortality (HR 1.50) in established CKD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: